Breast cancer (invasive) · line 1 · Pembrolizumab + chemo (TNBC neoadjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-PEMBRO-CHEMO-TNBC-NEOADJUVANT`

ID	`IND-BREAST-TNBC-EARLY-NEOADJUVANT`
Type	Indication
Status	reviewed 2026-05-09 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-EARLY-2024` `SRC-KEYNOTE-522-SCHMID-2022` `SRC-NCCN-BREAST-2025`

Notes

Stage II-III TNBC standard. KEYNOTE-522 benefit independent of PD-L1 status (early-disease setting, distinct from metastatic where PD-L1 matters per KEYNOTE-355). Continuation: 9 additional pembro adjuvant cycles to complete ~1 year immunotherapy. BRCA+ residual disease: consider olaparib (OlympiA) — separate Indication.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L

Red flag

RF-BREAST-STAGE-IV-METASTATIC - Metastatic (stage IV) breast cancer: presence of distant metastasis (M1 per TNM 8th editi...